Professor | Xia Hongping | Asia Growth Partners

	Upload Avatar (500 x 500)
Name	Xia Hongping
Contact Information	xiahongping@njmu.edu.cn
Language ability	Chinese, English
Province	Jiangsu

Upload Avatar (500 x 500)

Name

Xia Hongping

Contact Information

xiahongping@njmu.edu.cn

Language ability

Chinese, English

Province

Jiangsu

University/Lab Affiliation and Title	Nanjing Medical University
Faculty	Basic Medical Sciences
Academic Background & Achievements	2011 - PhD in Chemical Biology and Oncology: University of Hong Kong 2007 - Master's in Pathology and Pathophysiology: Sun Yat-sen University 2004 - Bachelor's in Clinical Medicine: Wannan Medical College
Work Experience	2017-present - Nanjing Medical University - Professor 2012-2017 - National Cancer Centre Singapore - Research Fellow
Awards	2018: Asia-Pacific Primary Liver Cancer Expert Meeting, Young Investigator Award 2018: Henan Province Medical Science and Technology Progress Award, First Prize 2017: Nanjing Medical University Discipline Construction Work 'Advanced Individual' 2017/2018: The Liver Week, Incheon, Korea, Best Presentation Award 2015/2016: SingHealth Publish! Award (Outstanding) 2015: The 23rd Asia Pacific Cancer Conference, Bali, Indonesia, Best Oral Presentation Award 2012: International Society for Cell and Gene Therapy of Cancer Conference, Beckman Poster Prize No.1 2010: Eurasia-Pacific Uninet Science and Technology Scholarships (Austria)

University/Lab Affiliation and Title

Nanjing Medical University

Faculty

Basic Medical Sciences

Academic Background & Achievements

2011 - PhD in Chemical Biology and Oncology: University of Hong Kong
2007 - Master's in Pathology and Pathophysiology: Sun Yat-sen University
2004 - Bachelor's in Clinical Medicine: Wannan Medical College

Work Experience

2017-present - Nanjing Medical University - Professor
2012-2017 - National Cancer Centre Singapore - Research Fellow

Awards

2018: Asia-Pacific Primary Liver Cancer Expert Meeting, Young Investigator Award
2018: Henan Province Medical Science and Technology Progress Award, First Prize
2017: Nanjing Medical University Discipline Construction Work 'Advanced Individual'
2017/2018: The Liver Week, Incheon, Korea, Best Presentation Award
2015/2016: SingHealth Publish! Award (Outstanding)
2015: The 23rd Asia Pacific Cancer Conference, Bali, Indonesia, Best Oral Presentation Award
2012: International Society for Cell and Gene Therapy of Cancer Conference, Beckman Poster Prize No.1
2010: Eurasia-Pacific Uninet Science and Technology Scholarships (Austria)

Areas of Focus	Molecular Pathology and Translational Medicine
Publications	EDIL3 is a novel regulator of epithelial mesenchymal transition controlling early recurrence of hepatocellular carcinoma., Xia H, Chen J, Shi M, Gao H, Sekar K, Seshachalam VP, Ooi LL, Hui KM., 2015 pH-Sensitive Nanoformulated Triptolide as a Targeted Therapeutic Strategy for Hepatocellular Carcinoma., Ling D, Xia H, et al., 2014 MiR-216a/217-induced epithelial-mesenchymal transition targets PTEN and SMAD7 to promote drug resistance and recurrence of liver cancer., Xia H, et al., 2013 pH-Sensitive Pt Nanocluster Assembly Overcomes Cisplatin Resistance and Heterogeneous Stemness of Hepatocellular Carcinoma., Xia H, et al., 2016 MELK is an oncogenic kinase essential for early hepatocellular carcinoma recurrence., Xia H, et al., 2016 ECT2 regulates the Rho/ERK signalling axis to promote early recurrence in human hepatocellular carcinoma., Chen J, Xia H, et al., 2015 The microtubule-associated protein PRC1 promotes early recurrence of hepatocellular carcinoma in association with the Wnt/β-catenin signalling pathway., Chen J, MuthukumarRajasekaran, Xia H, et al., 2016 Single-layer MoS2 nanosheet grafted upconversion nanoparticles for near-infrared fluorescence imaging-guided deep tissue cancer phototherapy., Han J, Xia H, Wu Y, Kong SN, Deivasigamani A, Xu R, Hui KM, Kang Y., 2016 Emergence of aspirin as a promising chemopreventive and chemotherapeutic agent for liver cancer., Xia H, Hui KM., 2017 Simultaneous silencing of ACSL4 and induction of GADD45B in hepatocellular carcinoma cells amplifies the synergistic therapeutic effect of aspirin and sorafenib., Xia H, Lee KW, Chen J, Kong SN, Sekar K, Deivasigamani A, Seshachalam VP, Goh BKP, Ooi LL, Hui KM., 2017 CDK1-mediated BCL9 phosphorylation inhibits clathrin to promote mitotic Wntsignalling., Chen J, Rajasekaran M, Xia H, et al., 2018 The dimer-dependent catalytic activity of RAF family kinases is revealed through characterizing their oncogenic mutants., Yuan J, Ng WH, Lam PYP, Wang Y, Xia H, et al., 2018

Areas of Focus

Molecular Pathology and Translational Medicine

Publications

EDIL3 is a novel regulator of epithelial mesenchymal transition controlling early recurrence of hepatocellular carcinoma., Xia H, Chen J, Shi M, Gao H, Sekar K, Seshachalam VP, Ooi LL, Hui KM., 2015
pH-Sensitive Nanoformulated Triptolide as a Targeted Therapeutic Strategy for Hepatocellular Carcinoma., Ling D*, Xia H*, et al., 2014
MiR-216a/217-induced epithelial-mesenchymal transition targets PTEN and SMAD7 to promote drug resistance and recurrence of liver cancer., Xia H, et al., 2013
pH-Sensitive Pt Nanocluster Assembly Overcomes Cisplatin Resistance and Heterogeneous Stemness of Hepatocellular Carcinoma., Xia H, et al., 2016
MELK is an oncogenic kinase essential for early hepatocellular carcinoma recurrence., Xia H, et al., 2016
ECT2 regulates the Rho/ERK signalling axis to promote early recurrence in human hepatocellular carcinoma., Chen J, Xia H, et al., 2015
The microtubule-associated protein PRC1 promotes early recurrence of hepatocellular carcinoma in association with the Wnt/β-catenin signalling pathway., Chen J, MuthukumarRajasekaran, Xia H, et al., 2016
Single-layer MoS2 nanosheet grafted upconversion nanoparticles for near-infrared fluorescence imaging-guided deep tissue cancer phototherapy., Han J*, Xia H*, Wu Y, Kong SN, Deivasigamani A, Xu R, Hui KM, Kang Y., 2016
Emergence of aspirin as a promising chemopreventive and chemotherapeutic agent for liver cancer., Xia H, Hui KM., 2017
Simultaneous silencing of ACSL4 and induction of GADD45B in hepatocellular carcinoma cells amplifies the synergistic therapeutic effect of aspirin and sorafenib., Xia H, Lee KW, Chen J, Kong SN, Sekar K, Deivasigamani A, Seshachalam VP, Goh BKP, Ooi LL, Hui KM., 2017
CDK1-mediated BCL9 phosphorylation inhibits clathrin to promote mitotic Wntsignalling., Chen J, Rajasekaran M, Xia H, et al., 2018
The dimer-dependent catalytic activity of RAF family kinases is revealed through characterizing their oncogenic mutants., Yuan J, Ng WH, Lam PYP, Wang Y, Xia H, et al., 2018

Molecular Pathology Translational Medicine Cancer Research Hepatocellular Carcinoma Oncology Tumor Biology Clinical Research Biomedical Science Pathophysiology Therapeutic Strategies

Cheng Liqin - Central South University

Desheng Xiao - Central South University

Luqing Zhao - Central South University

View All

Personal Information

Academic Information

Research

Contact us

No account yet?

Personal Information

Academic Information

Research

Contact us